Drug Trial Radar · NCT05711797
Pharmacokinetic Characteristics of Subjects with Hepatic Insufficiency and Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Nov 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Apr 12, 2023
Primary completion
Feb 6, 2024
Study completion Aug 9, 2024
Sponsor
- Lead sponsor
- Nanjing Zenshine PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this multicenter, open, single-dose, parallel controlled, Phase I clinical study is to Evaluate a single oral ZX-7101A PK in subjects with varying degrees of (mild or moderate) liver insufficiency compared with healthy subjects matched by age, weight, and sex. And to evaluate the the safety and tolerability of ZX-7101A by a single oral dose in subjects. The main questions it aims to answer are: * Evaluate a single oral ZX-7101A PK in subjects with varying degrees of (mild or moderate) liver dysfunction and healthy subjects with normal liver function matched for age, weight, and sex. * To evaluate the safety and tolerability of ZX-7101A by a single oral dose in subjects.
Conditions
- Influenza, Human
Interventions
ZX-7101A 80mgDrug
ZX-7101A a drug to treatment influenza in Chinese adults
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: From dosing to 15 days after medication
- AUCTime frame: From dosing to 15 days after medication
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shuguang Hospital, Shanghai University of Traditional Chinese Medicine
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.